Production of milligram quantities of numerous proteins for structural and functional studies requires an eYcient puriWcation pipeline. We found that the dual tag, his 6 -tag-maltose-binding protein (MBP), intended to facilitate puriWcation and enhance proteins' solubility, disrupted such a pipeline, requiring additional screening and puriWcation steps. Not all proteins rendered soluble by fusion to MBP remained soluble after its proteolytic removal, and in those cases where the protein remained soluble, standard puriWcation protocols failed to remove completely the stoichiometric amount of his 6 -tagged MBP generated by proteolysis. Both liabilities were alleviated by construction of a vector that produces fusion proteins in which MBP, the his 6 -tag and the target protein are separated by highly speciWc protease cleavage sites in the conWguration MBP-site-his 6 -site-protein. In vivo cleavage at the Wrst site by co-expressed protease generated untagged MBP and his 6 -tagged target protein.
The burgeoning genomic information now available makes vast numbers of proteins accessible for structural and functional studies, and many large-scale projects have developed automated protocols for amplifying, cloning, and expressing genes, and for screening proteins for desirable properties [1] [2] [3] [4] [5] . Similar strides have been made in streamlining protein puriWcation, but production of suYcient material for detailed structural and functional characterization remains labor-intensive and time-consuming [3, 4, 6, 7] . Typically, puriWcation is facilitated by fusing proteins to aYnity tags, most commonly a his-tag, which allows puriWcation by immobilized metal-ion aYnity chromatography (IMAC, [8] ). Additional tags are often attached to improve proteins' solubility, such as maltosebinding protein (MBP) [2] [3] [4] 9, 10] . In typical protein production pipelines, the resulting fusion proteins are Wrst screened for solubility, then puriWed by semi-robotic protocols in which the tags are removed by a speciWc protease such as the tobacco etch virus (TEV) protease [4, 6, 11, 12] . A second step, such as subtractive IMAC, then removes contaminating host proteins. When standard protocols of this design, as implemented by the Midwest Center for Structural Genomics (MCSG) [6] , were applied to targets appended with N-terminal his 6 -MBP tags, complications arose because of false positives (proteins scored as soluble in screens of fusion proteins but insoluble after removal of MBP) and by failure of the secondary IMAC step to remove completely the his 6 -MBP generated by TEV cleavage. Here we describe a new vector that alleviates these problems without modiWcation of established screening and puriWcation protocols.
Vector pMCSG19 (Fig. 1 , Table 1 ) is derived from the simple his 6 -tag-TEV-site vector, pMCSG7 [13] , which has been used routinely for the production of proteins within the MCSG. The new vector applies strategies developed by Waugh and colleagues [14, 15] to the problems outlined above. It encodes a leader sequence of MBP-TVMV-site-his 6 -tag-TEV-site, where TVMV-site refers to the recognition sequence of tobacco vein mottling virus (TVMV) protease, another highly speciWc plant viral protease similar to TEV protease but with distinct speciWcity [16] . This conWguration is distinct from the conventional arrangement used in most MBP fusions where the his-tag is not separated from MBP by a cleavage site, as occurs in vector pMCSG9 (Fig. 1B) , which encodes the leader his 6 -MBP-TEV-site. Expression Fig. 1 . Organization of pMCSG vectors. Vectors are based on the pET system of vectors (Novagen). All vectors contain the same LIC region and accept the same PCR products. (A) Expression region of pMCSG7. Following the T7 promoter, lac operator, and ribosome binding site (RBS) derived from pET21a, pMCSG7 encodes a leader sequence consisting of a his 6 -tag, a spacer and the TEV protease recognition sequence followed by a LIC region based on a central SspI site [13] . Restriction sites within the leader sequence encoding region allow insertion of modules or replacement of sequences, indicated by the darker regions in B and C (see Materials and methods). (B) Leader sequence encoding region of pMCSG9. Expression of genes cloned into the LIC site generates his 6 -MBP-target fusion proteins in which his 6 -MBP can be released by TEV protease cleavage. (C) Leader sequence region of pMCSG19. Expression of cloned genes produces N-terminal fusions of target proteins in which MBP is separated from the his 6 -tag by a TVMV protease recognition sequence. TVMV protease cleavage releases the his 6 -tagged target protein, and TEV protease cleavage gives the untagged target protein. -TEV  2755  5286  pMCSG9  his 6 -MBP-TEV  43713  6147  pMCSG19  MBP-TVMV-his 6 -TEV  45050/2711   c   6441 of proteins from pMCSG19 with co-expression of TVMV protease resulted in eYcient removal of MBP and eliminated false positives that occurred from pMCSG9. Separation of the his 6 -tag from MBP allowed established robotic puriWcation protocols to purify the soluble proteins successfully without modiWcation or addition of steps.
Materials and methods

Construction of pMCSG9 and pMCSG19
The vector pMCSG9 was constructed by inserting the gene encoding MBP into the KpnI site of vector pMCSG7 [13] . The MBP encoding region was generated by PCR using plasmid pRK793 [17] as template (a generous gift from David Waugh) and the primers 5Ј-TTTTAGATCTG ATGTCCCCTATACTAGGTTATTGG and 5Ј-TTTTGG TACCTGGGATATCGTAATCATCCGATTTTGGAG GATGGT (purchased from the Howard Hughes Medical Institute-Keck Laboratory of Yale University, New Haven, CT). The vector was digested with KpnI and dephosphorylated with calf intestinal phosphatase (Promega, Madison, WI), and ligated to the KpnI-treated PCR product. The resulting plasmids were screened for orientation and the expression region of a positive candidate was sequenced to verify that the sequence of MBP matched that encoded by pRK793. Vector pMCSG19 was constructed by replacing the region encoding the his 6 -tag in pMCSG7 (between NdeI and BglII, Fig. 1A ) with a sequence encoding MBP-TVMV-site-his 6 -tag. The MBP-TVMV-site portion of this region was ampliWed from vector pRK1035 [15] (Science Reagents, Inc.) by PCR using Platinum Pfx polymerase (Invitrogen) and the primers TTAAACATATGAAAATC GAAGAAGG and TTATAGGATCCACGCCAGAA GAGTGATGATGATGGTG (encoding the his 6 -tag on its complement) in 2£ strength reaction buVer with 1 mM Mg 2+ for 25 cycles. The PCR product was cleaved with NdeI and BamHI and ligated into pMCSG7 which had been treated with NdeI and BglII followed by calf intestinal phosphatase and gel puriWcation. The ampliWed and Xanking sequences of the resulting construct were veriWed by DNA sequencing.
Ligation-independent cloning into pMCSG vectors
Vectors were prepared for LIC by cleavage with SspI endonuclease, puriWcation by agarose gel electrophoresis, and treatment with T4 DNA polymerase in the presence of dGTP. Fifteen micrograms of vector DNA, puriWed with a Qiagen Plasmid Midi kit (Qiagen, Valencia, CA), were incubated with 75 U high concentration SspI (New England Biolabs) at 37°C for 2 h in a reaction volume of 60 l, then puriWed following agarose gel electrophoresis using a QiaEx II gel extraction kit. The material was then treated with 40 U LIC-qualiWed T4 DNA polymerase (Novagen, Madison, WI) and 2.5 mM dGTP in a volume of 40 l in 1£ commercial buVer supplemented with 5 mM DTT. Genes were ampliWed by PCR with primers encoding the LIC overhang [13] (sense: TACTTCCAATCCAATGCX followed by the genes' N-terminal sequences; antisense: TTATCCACTTCCAATG followed by the complement of a stop codon and of the C-terminus of the gene), puriWed with a QIAQuick PCR puriWcation kit (Qiagen), and treated with T4 polymerase as described above except in the presence of dCTP. Following annealing of 30-50 ng of this material with 15 ng LIC-prepared vector, the resulting plasmids were transformed into DH5 , and plasmids prepared from these transformants were introduced into BL21(DE3) containing the plasmid pRK1037 [15] (Science Reagents, Inc.). Transformants were isolated on LB plates containing 100 g/ml ampicillin and 30 g/ml kanamycin.
Expression and analysis of solubility
Cultures were grown at 37° in LB containing ampicillin and kanamycin (100 g/ l and 30 g/ l, respectively) to an OD 600 of 0.5 at which time the temperature was dropped to 20°C and protein synthesis was induced by addition of 1 mM IPTG. Cells were harvested the next morning, suspended in 0.1 M Tris/HCl, pH 8.0, incubated with lysozyme and DNase (rLysonase and Benzonase, respectively, Promega) for 30 min at room temperature, frozen brieXy, then sonicated. Following centrifugation at 6000g for 15 min, the soluble and insoluble fractions were analyzed for protein by denaturing gel electrophoresis.
Production of selenomethionyl proteins in non-sterile enriched minimal medium in 2-liter plastic bottles
Selenomethionyl proteins were produced in BL21(DE3)-a strain not auxotrophic for methionineusing feedback inhibition of methionine biosynthesis [18, 19] . Cultures were grown in 2-liter polyethylene terephthalate beverage bottles [20, 21] containing one liter of non-sterile M9 salts supplemented with glucose, glycerol, amino acids, trace metals and vitamins to increase the cell yield [22] [23] [24] [25] . Amendments were, per liter: glycerol, 5 g; glucose, 4.4 g; non-inhibitory amino acids (L-glutamate, 
L-threonine, L-phenylalanine, and 15 mg of selenomethionine; Medicillin, Catalog No. MD045004D) and 1 mM isopropylthio--D-galactoside (IPTG) were added, and the temperature dropped to 20°C. Cultures were incubated overnight, harvested the next morning, suspended in lysis buVer (50 mM Hepes, pH 7.8, containing 500 mM NaCl, 10 mM imidazole, 10 mM -mercaptoethanol, and 5% glycerol), and lysed by sonication. Proteins were puriWed by established protocols [6] .
Results
Salvaging poorly soluble proteins through MBP fusionspMCSG9
Insertion of the gene encoding MBP, ampliWed by PCR from the vector pRK739 [17] , into the leader sequence encoding region of pMCSG7 gave pMCSG9 ( Fig. 1 , Materials and methods). Resulting plasmids were screened for orientation and expression of a protein of the expected molecular weight of his-tagged MBP (the product of the vector before introduction of a target gene), and the sequence of the MBP gene and surrounding expression region was veriWed by DNA sequencing. During restriction analysis, we also discovered that a portion of the vector near the Ap R gene was larger than anticipated, both in pMCSG9 and its parent, pMCSG7. Sequencing of this region revealed that a mutation in one of the SspI sites that were removed from the parent of pMCSG7, pET21a, during its construction resulted in retention of 129 additional bases of the parental vector. The mutation and retained bases appear not to aVect expression of cloned genes: over 2000 proteins have been produced in good yield from pMCSG7, leading to the deposition of over 200 structures in the Protein Data Bank. Vector sequences are available at http://www.bio.anl.gov/terrestrialr/microbiology1.html.
As expected [9, 10] , fusion to MBP eVectively enhanced the solubility of poorly soluble bacterial proteins. PCR products encoding 134 S. typhimurium proteins that were poorly soluble when produced from pMCSG7 were introduced into pMCSG9 and reevaluated (Table 2 ). These proteins were originally scored as poorly soluble (Solubility Score 1) when screened by robotic protocols [26] . Proteins in this category are visible on gels but only at an abundance similar to host proteins, and normally are not carried forward to puriWcation in the structure determination pipeline. Fusion to MBP eVectively redistributed these proteins in the spectrum of solubility scores, some appearing to become less soluble, but more improving in solubility (Table 2) . Sixty-four of the proteins (46%) were improved to Solubility Score 2 or 3 (soluble or highly soluble, respectively) by fusion to MBP. Proteins of Solubility Score 2 are clearly visible on gels in amounts greater than host proteins, and those of Solubility Score 3 are abundant, at far higher amounts than host proteins. Proteins in these categories routinely proceed to puriWcation. These results substantiate, with a large data set, the anticipated eVectiveness of MBP in salvaging poorly soluble proteins and allowing them to reenter the puriWcation pipeline. However, we found that proteins produced from pMCSG9 failed to give target protein of suYcient purity to proceed to crystallization trials after puriWcation by semi-automated protocols that were highly eVective for soluble his 6 -tagged proteins [6] . In general, a minimum of 10 mg of protein of at least 95% purity is required. None of 38 poorly soluble proteins that were made soluble by fusion to MBP satisWed these criteria, either due to precipitation after removal of MBP or failure of the second subtractive IMAC to remove completely the stoichiometric amount of his 6 -tagged MBP generated by TEV protease cleavage.
In vivo cleavage to release untagged MBP from fusion proteins-pMCSG19
Rather than adapt screening and puriWcation protocols to accommodate these limitations of MBP fusion proteins produced from pMCSG9, we modiWed the expression vector to bypass them. Strategies developed by Waugh and colleagues [14, 15] were adapted to design pMCSG19 (Fig. 1, Table 1 ). To construct the vector, we replaced the region of pMCSG7 encoding the N-terminal his 6 -tag with a region encoding MBP, a protease site, and a his 6 -tag (Materials and methods). Sequencing of the resulting construct veriWed the sequence of the ampliWed fragment and surrounding components of the expression region. Expression of genes introduced into pMCSG19 by LIC generates target proteins fused to an N-terminal leader of untagged MBP followed, in order, by a TVMV protease recognition sequence, a his-tag, and a TEV protease recognition sequence. Cleavage of these proteins with TVMV protease generates untagged MBP and a target protein with a his 6 -TEV-site leader identical to that produced from pMCSG7 except with an N-terminal serine instead of methionine preceding the his 6 -tag. If produced in cells co-expressing TVMV protease, cleavage will occur in vivo [15] .
Sixteen proteins, picked at random from the original set of 38, whose solubility was improved by fusion to MBP but Table 2 EVect of fusion to MBP on the solubility of 134 proteins in robotic screening a Solubility assessment was based on visual inspection gels of the soluble fraction of cell extracts. Solubility Scores are: 0, insoluble; 1, poorly soluble; 2, moderately soluble; and 3, highly soluble. Proteins in category 0 were not detected on gels of soluble fractions of cell lysates. Those in category 1 were present in amounts less than major host proteins. Category 2 proteins were more abundant than any host protein, and category 3 proteins dominated protein expression. Of 134 proteins that were poorly soluble when produced from pMCSG7 (his 6 -tag-TEV-site leader), 62 (46%) were improved to Solubility Score 2 or 3 when produced from pMCSG9 with the leader his 6 -tag-MBP-TEV-site.
Vector
Solubility Score   a   0  1  2  3   pMCSG7  0  134  0  0  pMCSG9  28  44  36  26 which failed to give pure protein after standard puriWcation (Table 3) , were used to evaluate pMCSG19. The available PCR products encoding the proteins were introduced into pMCSG19 by LIC and transformed into BL21(DE3) cells containing vector pRK1037 [15] . This plasmid encodes TVMV protease under control of the P L -tetO promoter. In hosts that do not produce the Tet repressor, such as BL21(DE3), the plasmid produces TVMV protease constitutively, and proteins produced from pMCSG19 are cleaved at the TVMV site in vivo. Following induction, cells were lysed, fractionated by centrifugation, and the soluble and insoluble fractions analyzed by polyacrylamide gel electrophoresis (Fig. 2) .
The predominant protein present in all lanes of the soluble fraction ( Fig. 2A) is MBP released by TVMV cleavage. The other predominant band below the MBP band in some Table 3 Proteins expressed in pMCSG19 a Lane number in Fig. 2 Table 3 .
of the lanes is target protein that remained soluble after cleavage from MBP. Analysis of the insoluble fraction (Fig. 2B) 6 and 8 (Fig. 2B) would disqualify them, as would the doublet for the soluble target protein in lane 10. The remaining eight proteins were produced on a large scale and puriWed (see below). In summary, only half of these target proteins were deemed satisfactory for puriWcation; the others represent false positives that were previously scored as satisfactory based on analysis of the his 6 -MBP fusion proteins generated from pMCSG9. The MBPhis 6 -target fusion proteins generated by pMCSG19 were also soluble (data not shown). Thus, in vivo cleavage of proteins produced from pMCSG19 eVectively eliminated false positives without addition of a protease cleavage step to the screening protocols.
In those cases where fusion to MBP truly improved a protein's solubility, the his 6 -MBP leader attached by production from pMCSG9 compromised puriWcation by protocols that were highly eVective for simple his 6 -tagged proteins. Proteolytic cleavage with TEV generated a stoichiometric amount of his 6 -MBP, which consistently failed to bind well to the second, subtractive IMAC of standard protocols, as illustrated in the puriWcation of a representative target protein (Fig. 3A) . For proteins produced from pMCSG9, the Wrst IMAC yields the partially puriWed his 6 -MBP-target fusion protein (Fig. 3A, lanes 1-4) . Hydrolysis of this protein by TEV protease generates his 6 -MBP (larger protein in Fig. 3A , lane 5) and the target protein (lower band). When this material is passed through the subtractive IMAC column, his-tagged MBP fails to bind well under the standard conditions, resulting in severe contamination of the target protein in the Wnal eluted fraction (Fig. 3A, lanes   5-7) . In contrast, when proteins are produced from pMCSG19 in a host expressing TVMV protease (Fig. 3B) , MBP is cleaved away from the target protein in vivo (Fig. 3B, lane 1) . Because of the design of the vector, this MBP is not his-tagged, and passes through the Wrst IMAC column (Fig. 3B, lane 2) . The target protein, which is directly his-tagged, is retained, and elutes in partially puriWed form (Fig. 3B, lane 4) . Hydroylsis of this protein with TEV protease and subtractive IMAC chromatography generates target protein of suYcient purity to initiate crystallization trials (Fig. 3B, lanes 5-7) . Production of proteins from pMCSG19 with in vivo co-expression of TVMV protease thereby resolved the puriWcation problem without modiWcation of protocols or addition of tertiary steps.
Production of selenomethionyl proteins from pMCSG19
Selenomethionyl derivatives of soluble proteins were produced by culturing cells in 2-liter polyethylene terephthalate beverage bottles [20] in 1 liter of non-sterile M9 salts supplemented with additional nutrients (Materials and methods). The medium and conditions were identical to those described previously [21] but with the addition of glycerol, non-inhibitory amino acids, trace metals and vitamins [18, [22] [23] [24] [25] to improve the yield of cells. Under these conditions, cell yields were two-to three-fold higher compared to those attained in unsupplemented medium, typically generating OD 600 values of 4-12, depending on the protein expressed, with no detriment to expression or in vivo cleavage. Fig. 4 shows the partial puriWcation of three proteins through the Wrst IMAC step and is representative of the strong expression, eYcient cleavage by coexpressed TVMV protease, and complete removal of MBP typically obtained. The three proteins were further puriWed by subtractive IMAC to remove trace Escherichia coli proteins [6] , and analyzed for selenomethionine incorporation. Amino acid analysis failed to detect methionine in any of the three proteins, consistent with selenomethionine Fig. 3 . PuriWcation of target proteins produced from pMCSG9 and pMCSG19. A representative puriWcation by standardized puriWcation protocols [6] of APC25420 produced from (A) pMCSG9, and (B) pMCSG19. In both cases, numbered lanes contain (1) cell extract, (2-4) Wrst IMAC Xow-through, wash, and eluate, respectively, (5) TEV protease treated eluate, (6-7) subtractive IMAC Xow-through and wash, respectively. For proteins produced from pMCSG9 (A), the Wrst IMAC yields partially puriWed his 6 incorporation of 90% or more [21] . Yields per liter of puriWed target proteins produced in the amended medium were consistently two-fold or more higher than those obtained from unamended medium, allowing production of suYcient protein for crystallization trials from a single bottle, halving the number of cultures required to produce each protein. The eight soluble target proteins were produced on a large scale as their selenomethionyl derivatives and puriWed. Six generated greater than 10 mg of protein of greater than 95% purity (average yield for these 6 was 39 mg per liter of culture, range 14-84 mg). These were carried forward to crystallization trials; two gave crystals, and one was solved.
Discussion
Because many studies support the eVectiveness of fusion to MBP for improving the solubility of proteins [2-4,9,10], we assessed the potential of using MBP fusions as a salvage pathway for poorly soluble proteins in a high-throughput protein production pipeline. A large set of S. typhimurium proteins that were poorly soluble when expressed with a simple his 6 -tag was re-evaluated as MBP fusions (Table 2) . Fusion to MBP in eVect redistributed the proteins in the spectrum of solubility, generating a spread from completely insoluble to highly soluble fusion proteins, but with a strong bias toward improved solubility. Of the 134 proteins, only 28 (20%) became less soluble as MBP fusions, whereas the solubility of 62 (45%) improved upon fusion to MBP. Twenty-six proteins (19%) were deemed highly soluble and 36 (26%), moderately soluble based on the intensity of bands in protein gels of the soluble fraction of lysates. PuriWcation of proteins in these two categories by standard protocols is considered likely to produce greater than 10 mg of pure protein (the amount needed for crystallization screening trials) and they, therefore, are passed forward into the labor-intensive large-scale puriWcation phase of the pipeline. The results obtained from these 134 proteins justify incorporation of MBP fusions into high-throughput screening and puriWcation pipelines for salvaging poorly soluble proteins.
The apparent solubility of proteins attached to MBP, however, was often transitory; in these cases, proteolytic removal of MBP resulted in aggregation or precipitation of the target protein. The large, highly soluble MBP protein apparently allowed intrinsically insoluble proteins to partition into the soluble fraction as long as they remain linked to MBP. If carried forward to puriWcation protocols designed for truly soluble proteins, such proteins will fail to give enough pure material for structural or functional characterization, resulting in considerable wasted time and eVort. Evaluation of solubility after proteolysis could detect false positives of this sort, but would require an additional step in screening protocols. For target proteins expressed from pMCSG19, in vivo removal of MBP by co-expressed TVMV protease eVectively eliminated these false positives (Fig. 2) . Of sixteen proteins, all of which were soluble as MBP fusions, only about half remained soluble after in vivo removal of MBP (Fig. 2A) . The intensity of the target protein band (seen below the predominant band of MBP in all lanes) suggested eleven were rendered suYciently soluble by transitory fusion to MBP (Solubility Score 2 or 3, see Table 2 ), but analysis of the insoluble fraction (Fig. 2B) provided additional insight into the suitability of the proteins for puriWcation. The large amount of insoluble target protein in lanes 6 and 8 suggested these proteins would be more prone to aggregation and precipitation during processing, causing them to be rejected, as was the target in lane 10 because it produced a doublet. PuriWcation of the remaining eight proteins supported the utility of evaluating the insoluble fraction as well as the soluble. Six of these proteins yielded enough pure protein to pass on to crystallization trials, but those that failed had partitioned evenly between the soluble and insoluble fractions in the solubility analysis (lanes 3 and 4 of Fig. 2 ). Of the six that entered crystallization trials, two crystallized, and one was solved. Whereas this data set is clearly too small to measure the eVectiveness of pMSCG19 precisely, it strongly supports the potential utility of the vector in a salvage pathway for poorly soluble target proteins.
A second complication arose during puriWcation of his 6 -MBP-tagged proteins derived from pMCSG9. The stoichiometric amount of his 6 -MBP produced by TEV protease cleavage of the fusion proteins was not removed eVectively by the second, subtractive IMAC column of standard puriWcation protocols, resulting in contamination of the Wnal product with his 6 -MBP (Fig. 3) . Altered or additional puriWcation steps, such as gradient elution, use of larger columns, or subsequent ion-exchange or gel-Wltration steps, successfully separated target proteins from his-tagged Fig. 2 , which are APC25420, APC25436, and APC25439. In each panel, the lanes contain: (1) total soluble protein extract (loaded onto IMAC column), (2) unbound material that passed through the column, (3) column wash, and (4) eluted proteins. Subsequent cleavage by TEV protease followed by subtractive IMAC generated protein of >95% purity. Samples of these more highly puriWed proteins were analyzed for selenomethionine incorporation.
MBP, but each approach seriously disrupted the general laboratory workXow and increased the eVort required to purify the individual proteins. Vector pMCSG19 eliminates his-tagged MBP by placing a second highly speciWc protease cleavage site, the TVMV-site, between an N-terminal, untagged MBP and the his-tag, which is followed by the standard TEV protease cleavage site (Fig. 1) . Combined with in vivo cleavage at the TVMV site by co-expressed TVMV protease, pMCSG19 generates untagged MBP plus a simple his 6 -tagged target protein identical to that produced from pMCSG7 except for the presence of an N-terminal serine instead of methionine. During standard puriWcation, the untagged MBP passes through the initial IMAC column unretarded. The stoichiometric 'contaminant' is thus removed eYciently, and subsequent steps of the puriWcation are identical to those used for simple his 6 -tagged targets produced from pMCSG7.
Use of pMCSG19 and in vivo cleavage with TVMV protease provides a satisfactory system for producing most target proteins via a very streamlined screening and puriWcation pipeline. The validation experiments described here were limited to small (<40 kDa) bacterial proteins, but are suYciently compelling to justify the use of pMCSG19 in standard production protocols. Accordingly, we have initiated routine salvaging of poorly soluble proteins by reprocessing in pMCSG19. The approach represents an additional application of in vivo cleavage by highly speciWc proteases [14, 15] , and the strategy of incorporating a second high-speciWcity protease cleavage site to remove an untagged chaperone component in vivo could be of value in other protein production pipelines. Time and eVort that might have been spent pursuing false positives or performing additional screening or puriWcation steps can be spent on other crucial tasks. The process is also fully compatible with production of selenomethionyl derivatives for crystallography. High yields of target proteins with very eYcient incorporation of selenomethionine were obtained in enriched deWned medium using a non-auxotrophic host and commercially available, premixed medium components. For the six proteins successfully puriWed, the average yield was 39 mg per liter of culture. Such high-yields and incorporation can be obtained as well in similar production media employing autoinduction and incorporating isotopically labeled amino acids for nuclear magnetic resonance experiments [23] [24] [25] . In addition to the application described here, highly enriched deWned media and vectors of the general conWguration, tag1-site1-tag2-site2-protein, could be exploited for other purposes, including functional analyses of proteins.
